Skip to content

US · DCTH · MEDICAL - DEVICES

Delcath Systems, Inc. (DCTH) intrinsic value and stock valuation

$18.79as of 2026-11-21 · Mkt cap 436.01M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Delcath Systems, Inc. DCF and intrinsic value

InvestorsCraft values DCTH with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from DCTH’s statements →

Delcath Systems, Inc. Graham Number

Graham Number: $2.29d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Devices Queensbury, NY 12804 delcath.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$85.2M+120.1% 5y CAGRd
20112025
Net income
$2.7M
20112025
Free cash flow
$21M
20112025
Total equity
$111.2M+38.2% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$85.2M$37.2M$2.06M$2.72M$3.56M
Operating income$660K-$-12.41M-$-38.18M-$-33.85M-$-24.53M
Net income$2.7M-$-26.39M-$-47.68M-$-36.51M-$-25.65M
EPSd$67.6K-$-925.64K-$-2.94M-$-4.12M-$-3.59M
Operating cash flow$22.5M-$-18.68M-$-31.25M-$-24.95M-$-22.6M
Capital expenditure-$-1.55M-$-560K-$-60K-$-210K-$-140K
Free cash flow$21M-$-19.24M-$-31.31M-$-25.16M-$-22.75M
Total assets$123.6M$76.6M$38.6M$17.9M$33.1M
Total debt$940K$1.04M$10.2M$15.9M$16.3M
Net debt-$-42.52M-$-31.37M-$-2.46M$8.2M-$-6.55M
Total equity$111.2M$68.8M$15.8M-$-5.86M$12M
Cash and short-term investments$91M$53.2M$32.5M$7.67M$22.8M
Income statement
20252024202320222021
Revenue$85.2M$37.2M$2.06M$2.72M$3.56M
Cost of revenue$11.8M$6.19M$640K$690K$670K
Gross profit$73.4M$31M$1.43M$2.03M$2.88M
Research and development expenses$29.3M$13.9M$17.5M$18.6M$13.8M
Selling, general and administrative expenses$43.5M$29.6M$22.1M$17.3M$13.6M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$72.8M$43.4M$39.6M$35.9M$27.4M
Cost and expenses$84.6M$49.6M$40.3M$36.6M$28.1M
Interest income$2.92M$120K$0.00$0.00$0.00
Interest expense$0.00$0.00$1.44M$2.69M$1.19M
Depreciation and amortization$350K$230K$400K$130K$150K
Ebitda$3.86M-$-26.16M-$-45.84M-$-33.69M-$-24.32M
Operating income$660K-$-12.41M-$-38.18M-$-33.85M-$-24.53M
Total other income/expenses, net$2.85M-$-13.98M-$-9.5M-$-2.65M-$-1.12M
Income before tax$3.51M-$-26.39M-$-47.68M-$-36.51M-$-25.65M
Income tax expense$810K$0.00$0.00$0.00$0.00
Net income$2.7M-$-26.39M-$-47.68M-$-36.51M-$-25.65M
Weighted average shares outstanding$35.8M$28.5M$16.2M$8.86M$7.15M
Weighted average diluted shares outstanding$39.9M$28.5M$16.2M$8.86M$7.15M
Balance sheet
20252024202320222021
Cash and short-term investments$91M$53.2M$32.5M$7.67M$22.8M
Net receivables$12.9M$11.1M$480K$370K$40K
Inventory$10.3M$6.93M$3.32M$2M$1.41M
Total current assets$119.5M$73.8M$37.2M$16.2M$31.2M
Property, plant and equipment, net$4.1M$2.83M$1.46M$1.71M$1.97M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$4.1M$2.83M$1.46M$1.71M$1.97M
Total assets$123.6M$76.6M$38.6M$17.9M$33.1M
Accounts payable$2.66M$960K$1.01M$2.02M$640K
Short-term debt$100K$100K$10.2M$8.03M$1.04M
Deferred revenue$0.00$0.00$0.00$0.00$170K
Total current liabilities$11M$6.14M$16.5M$14.7M$5.95M
Long-term debt$830K$930K$0.00$7.84M$15.2M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$1.46M$1.7M$6.39M$8.99M$15.2M
Capital lease obligations$940K$1.04M$40K$190K$620K
Total liabilities$12.4M$7.84M$22.8M$23.7M$21.2M
Common stock$350K$330K$230K$100K$80K
Retained earnings-$-528.85M-$-531.55M-$-505.16M-$-457.48M-$-420.98M
Accumulated other comprehensive income (loss)$570K$80K$140K-$-80K$20K
Total equity$111.2M$68.8M$15.8M-$-5.86M$12M
Total investments$47.6M$20.8M$19.8M$0.00$0.00
Total debt$940K$1.04M$10.2M$15.9M$16.3M
Net debt-$-42.52M-$-31.37M-$-2.46M$8.2M-$-6.55M
Cash flow statement
20252024202320222021
Net income$2.7M-$-26.39M-$-47.68M-$-36.51M-$-25.65M
Depreciation and amortization$350K$230K$130K$130K$150K
Stock-based compensation$24.2M$9.77M$8.15M$7.94M$7.83M
Change in working capital-$-3.07M-$-15.52M-$-910K$2.11M-$-5.76M
Accounts receivable-$-850K-$-10.65M$120K-$-320K$10K
Inventory-$-3.32M-$-3.61M-$-1.32M-$-590K-$-560K
Accounts payable$4.77M$480K-$-200K$1.8M-$-1.14M
Net cash provided by operating activities$22.5M-$-18.68M-$-31.25M-$-24.95M-$-22.6M
Investments in property, plant and equipment-$-1.55M-$-560K-$-60K-$-210K-$-140K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-26.59M-$-980K-$-19.71M-$-210K-$-140K
Common stock issued$21.1M$7.02M$23.1M$10.9M$3.92M
Common stock repurchased-$-6M$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$15.1M$39.4M$51.8M$10.1M$20.8M
Net change in cash$11M$19.7M$870K-$-15.13M-$-1.8M
Cash at end of period$43.5M$32.4M$12.7M$11.8M$27M
Operating cash flow$22.5M-$-18.68M-$-31.25M-$-24.95M-$-22.6M
Capital expenditure-$-1.55M-$-560K-$-60K-$-210K-$-140K
Free cash flow$21M-$-19.24M-$-31.31M-$-25.16M-$-22.75M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Delcath Systems, Inc.

        Delcath Systems, Inc. is an interventional oncology firm operating in the United States and Europe, dedicated to developing treatments for both primary and secondary liver cancers. Its leading investigational product is the HEPZATO KIT, a unique hepatic delivery system for melphalan that targets high-dose chemotherapy specifically to the liver. This innovative approach aims to substantially reduce systemic drug exposure and mitigate associated side effects. HEPZATO's clinical evaluation is advancing through the FOCUS trial, which is designed to assess the objective response rate in individuals with metastatic uveal melanoma whose disease is primarily concentrated in the liver. Furthermore, the company offers a separate version of HEPZATO as a medical device in Europe, marketed under the CHEMOSAT Hepatic Delivery System brand (or simply CHEMOSAT). This system empowers European medical centers to manage a diverse array of liver cancer conditions. Delcath Systems, Inc. was established in 1988, with its corporate headquarters situated in New York, New York.

        CEO
        Gerard J. Michel
        Employees
        156
        Beta
        0.49

        Explore

        Frequently asked questions

        What is the intrinsic value of Delcath Systems, Inc. (DCTH)?

        Delcath Systems, Inc. (DCTH) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is DCTH undervalued?

        DCTH trades at a price of $18.79 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.